{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:49:08Z","timestamp":1787064548137,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771408"],"award-info":[{"award-number":["81771408"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771409"],"award-info":[{"award-number":["81771409"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81701541"],"award-info":[{"award-number":["81701541"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2019.00868","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T10:07:01Z","timestamp":1565258821000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Diseases in Children in Central South China: Clinical Features, Treatments, Influencing Factors, and Outcomes"],"prefix":"10.3389","volume":"10","author":[{"given":"Leilei","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciliu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1471-4159.1989.tb10930.x","article-title":"Differential ultrastructural localization of myelin basic protein,myelin\/oligodendroglial glycoprotein, and 2\u2032, 3\u2032-cyclic nucleotide 3\u2032-phosphodiesterase in the CNS of adult rats","volume":"52","author":"Brunner","year":"1989","journal-title":"J Neurochem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/ana.21916","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease","volume":"66","author":"Brilot","year":"2009","journal-title":"Ann Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/1352458510389220","article-title":"Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children","volume":"17","author":"Lalive","year":"2011","journal-title":"Mult Scler"},{"key":"B5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/jnnp-2014-308346","article-title":"Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein","volume":"86","author":"Baumann","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Nuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler."},{"key":"B10","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/ene.13602","article-title":"Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome","volume":"25","author":"Wong","year":"2018","journal-title":"Eur J Neurol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O'Connor","year":"2007","journal-title":"Nat Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","article-title":"Treatment Approaches for MOG-Ab-Associated demyelination in children","volume":"21","author":"Hacohen","year":"2019","journal-title":"Curr Treat Options Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/dmcn.13649","article-title":"\u2018Leukodystrophy-like\u2019 phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"60","author":"Hacohen","year":"2018","journal-title":"Dev Med Child Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3389\/fimmu.2017.00529","article-title":"Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases","volume":"8","author":"Peschl","year":"2017","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jneuroim.2017.09.005","article-title":"Anti-N-methyl-D-aspartate receptor encephalitis in children of Central South China: Clinical features, treatment, influencing factors, and outcomes","volume":"312","author":"Wang","year":"2017","journal-title":"J Neuroimmunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.msard.2018.01.007","article-title":"Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis","volume":"20","author":"Fan","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B19","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1212\/WNL.0000000000004117","article-title":"Diagnostic algorithm for relapsing acquired demyelinating syndromes in children","volume":"89","author":"Hacohen","year":"2017","journal-title":"Neurology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs","volume":"75","author":"Hamid","year":"2018","journal-title":"JAMA Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00415-016-8147-7","article-title":"Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes","volume":"263","author":"Sep\u00falveda","year":"2016","journal-title":"J Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica: state-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1177\/1352458516678474","article-title":"Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders","volume":"23","author":"Montcuquet","year":"2017","journal-title":"Mult Scler"},{"key":"B27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WCO.0000000000000446","article-title":"Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they?","volume":"30","author":"Reindl","year":"2017","journal-title":"Curr Opin Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.msard.2018.12.001","article-title":"Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination","volume":"28","author":"Zhou","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"B29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/1352458515587751","article-title":"Clinical and MRI phenotype of children with MOG antibodies","volume":"22","author":"Fernandez-Carbonell","year":"2016","journal-title":"Mult Scler"},{"key":"B30","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.braindev.2015.02.006","article-title":"Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies","volume":"37","author":"Hino-Fukuyo","year":"2015","journal-title":"Brain Dev"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.00868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T20:36:27Z","timestamp":1569098187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.00868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,8]]},"references-count":30,"alternative-id":["10.3389\/fneur.2019.00868"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2019.00868","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,8]]},"article-number":"868"}}